Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, and welcome to Intelia Therapeutics' second quarter conference call. My name is Chloe, and I will be your conference operator today. Please be advised that today's call is being recorded. I would now like to turn the call over to Jason Fredette, Vice President of Investor Relations and Corporate Communications at Intelia. Please proceed. Thank you, operator, and hello, everyone. Earlier this morning, we issued a press release outlining recent business updates in our second quarter financial results. This document can be found on the Investors and Media section of Intelia's website at inteliatx.com. At this time, I would like to take a minute to remind listeners that during this call, Intelia management may make certain forward-looking statements. We ask that you refer to our SEC filings available at sec.gov for a discussion of potential risks and uncertainties. All information presented on this call is current as of today, and Intelia undertakes no duty to update this information unless required by law. Joining me on the call are John Leonard, our chief executive officer, and Ed Dulac, our chief financial officer. With that, I'll now turn the call over to John to begin our business discussion. Thank you, Jason, and good morning, everyone. We're excited to be speaking with you to recap the tremendous progress we made in our phase three development programs of Flamvozi in hereditary angioedema, or HAE, and Nexi in trans-thyretin amyloidosis, or ATTR. The full results of our Phase 3 HALO trial in HAE position us very well for potential approval and launch of the world's first in vivo gene editing product in the first half of next year. We also have gained important new genomic insights that further our understanding of NEXE's profile and could help position us ev...